铋
2019年冠状病毒病(COVID-19)
抗菌剂
行动方式
2019-20冠状病毒爆发
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)
作用机理
抗生素耐药性
抗药性
机制(生物学)
药品
纳米技术
药物发现
化学
计算生物学
微生物学
生物信息学
药理学
甲硝唑
生物
组合化学
抗生素
作者
Hongyan Li,Xueying Wei,Hongzhe Sun
标识
DOI:10.1021/acs.accounts.5c00471
摘要
newly developed bismuth compounds serve as novel metalloantibiotics to combat AMR. Moreover, the ability of bismuth to disrupt key zinc finger proteins for the transcription and replication in coronavirus rendered its new potential in treating coronavirus infections, particularly SARS-CoV-1 and SARS-CoV-2. Combining clinically used bismuth drugs with N-acetyl cysteine (NAC), a thiol-containing drug, increases bismuth uptake in blood plasma to therapeutic levels for SARS-CoV-2 without apparent toxicity. Bismuth drugs, therefore, hold great potential for the treatment of viral infections.We anticipate that our mechanism-guided discoveries of bismuth's new therapeutic applications are poised to inspire researchers in relevant fields to rationally design drugs (and metallodrugs) and repurpose FDA-approved drugs, ultimately leading to the development of new effective therapeutics for combating emerging infectious diseases, which will positively impact human health and well-being.
科研通智能强力驱动
Strongly Powered by AbleSci AI